Kriya Therapeutics’ $100 Million Series B Financing

Goodwin Procter LLP advised Kriya Therapeutics on the deal, while Kirkland & Ellis advised Patient Square Capital.

Kriya Therapeutics announced the closing of a $100 Million Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies. The financing was led by Patient Square Capital, with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others. All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and the Juvenile Diabetes Research Foundation T1D Fund.

Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.

Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed and manufactured – improving speed to market and delivering significant reductions in the cost per dose. Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE™).

The Goodwin team was led by Deepa M. Rich (Picture) and Sam Zucker with invaluable support from William “Wynn” Stateman, Steven Green, Chris Denn and Samira Seraji.

The Kirkland team was led by corporate partner Michael Weisser and associate Carl Witkin, ESG & impact partner Alexandra Farmer, environmental transactions associate Donna Ni, and tax partner Mark Schwed and associate Dana Quinn.

Involved fees earner: Christopher Denn – Goodwin Procter; Steven Green – Goodwin Procter; Deepa Rich – Goodwin Procter; William Stateman – Goodwin Procter; Sam Zucker – Goodwin Procter; Alexandra Farmer – Kirkland & Ellis; Donna Ni – Kirkland & Ellis; Dana Quinn – Kirkland & Ellis; Mark Schwed – Kirkland & Ellis; Michael Weisser – Kirkland & Ellis; Carl Witkin – Kirkland & Ellis;

Law Firms: Goodwin Procter; Kirkland & Ellis;

Clients: Kriya Therapeutics; Patient Square Capital;

Martina Bellini

Author: Martina Bellini